NP5 fundamentals
An in-depth look to NEWRON PHARMACEUT. EO-,20 operating, investing, and financing activities
NP5 free cash flow for H2 23 is -4.51 M EUR. For 2023, NP5 free cash flow was -10.61 M EUR and operating cash flow was -10.6 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM